331 related articles for article (PubMed ID: 30194149)
21. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity.
Suck G; Branch DR; Smyth MJ; Miller RG; Vergidis J; Fahim S; Keating A
Exp Hematol; 2005 Oct; 33(10):1160-71. PubMed ID: 16219538
[TBL] [Abstract][Full Text] [Related]
22. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
[TBL] [Abstract][Full Text] [Related]
23. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
Liu Y; Zhou Y; Huang KH; Fang X; Li Y; Wang F; An L; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Cell Prolif; 2020 Aug; 53(8):e12858. PubMed ID: 32592435
[TBL] [Abstract][Full Text] [Related]
24. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells.
Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Front Immunol; 2018; 9():824. PubMed ID: 29740437
[TBL] [Abstract][Full Text] [Related]
25. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.
Caruso HG; Torikai H; Zhang L; Maiti S; Dai J; Do KA; Singh H; Huls H; Lee DA; Champlin RE; Heimberger AB; Cooper LJ
J Immunother; 2016 Jun; 39(5):205-17. PubMed ID: 27163741
[TBL] [Abstract][Full Text] [Related]
26. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
27. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
28. [Construction and functional analysis of EGFRvIII CAR-T cells co-expressing IL-15 and CCL19].
Chen W; Xian N; Lin S; Liao W; Chen M
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3787-3799. PubMed ID: 37805854
[TBL] [Abstract][Full Text] [Related]
29. AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.
Hamblett KJ; Kozlosky CJ; Siu S; Chang WS; Liu H; Foltz IN; Trueblood ES; Meininger D; Arora T; Twomey B; Vonderfecht SL; Chen Q; Hill JS; Fanslow WC
Mol Cancer Ther; 2015 Jul; 14(7):1614-24. PubMed ID: 25931519
[TBL] [Abstract][Full Text] [Related]
30. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
[TBL] [Abstract][Full Text] [Related]
31. Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.
Yvon ES; Burga R; Powell A; Cruz CR; Fernandes R; Barese C; Nguyen T; Abdel-Baki MS; Bollard CM
Cytotherapy; 2017 Mar; 19(3):408-418. PubMed ID: 28109751
[TBL] [Abstract][Full Text] [Related]
32. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
[TBL] [Abstract][Full Text] [Related]
33. Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma.
Zhang Q; Tian K; Xu J; Zhang H; Li L; Fu Q; Chai D; Li H; Zheng J
J Immunol Res; 2017; 2017():6915912. PubMed ID: 29423418
[TBL] [Abstract][Full Text] [Related]
34. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
Zhu H; You Y; Shen Z; Shi L
Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
36. Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
Rudek LS; Zimmermann K; Galla M; Meyer J; Kuehle J; Stamopoulou A; Brand D; Sandalcioglu IE; Neyazi B; Moritz T; Rossig C; Altvater B; Falk CS; Abken H; Morgan MA; Schambach A
Front Immunol; 2021; 12():751138. PubMed ID: 34804035
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.
Nakazawa T; Nakamura M; Matsuda R; Nishimura F; Park YS; Motoyama Y; Hironaka Y; Nakagawa I; Yokota H; Yamada S; Tamura K; Takeshima Y; Omoto K; Tanaka Y; Ouji Y; Yoshikawa M; Tsujimura T; Nakase H
J Neurooncol; 2016 Sep; 129(2):231-41. PubMed ID: 27393349
[TBL] [Abstract][Full Text] [Related]
38. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain.
Lee SJ; Kang WY; Yoon Y; Jin JY; Song HJ; Her JH; Kang SM; Hwang YK; Kang KJ; Joo KM; Nam DH
BMC Cancer; 2015 Dec; 15():1011. PubMed ID: 26704632
[TBL] [Abstract][Full Text] [Related]
39. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
40. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.
Kulemzin SV; Matvienko DA; Sabirov AH; Sokratyan AM; Chernikova DS; Belovezhets TN; Chikaev AN; Taranin AV; Gorchakov AA
BMC Med Genomics; 2019 Mar; 12(Suppl 2):44. PubMed ID: 30871576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
